HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-84
SponsorKocaeli University

About this trial

Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation.

This prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation.

The primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.

Eligibility criteria

Qualifiers

Patients aged 18 to 84 years

ASA physical status I-III

Patients scheduled to undergo ERCP

Patients who provide written informed consent

Disqualifiers

Recent history of upper respiratory tract infection

History of lung cancer

Chronic obstructive pulmonary disease

Asthma

Trial design

Treatments tested in this trial

  • High-flow nasal canula
  • Microstream advance nasal cannula

Treatment groups

74 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators